Akums Drugs & Pharmaceuticals Ltd Q4 FY26 Results & Concall Highlights: Revenue, Margins & Order Book

Q4 FY26 earnings call analysis: revenue, margin, capex, fundraise and order book outlook from management commentary.

Published 24 May 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹11.4K Cr

CDMO segment expects double-digit volume growth in H1 FY27; overall revenue growth guidance not specifically stated yet. CDMO business expects double-digit volume growth in H1 FY27 with similar margin profile as current (around 13-14%) and potential improvement due to new European and Zambia contracts leading to better margins (potentially 15-16%).

From Akums Drugs & Pharmaceuticals Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.

Price

₹750

Market Cap

₹11.4K Cr

P/E Ratio

37.5

How does Akums Drugs & Pharmaceuticals Ltd rank in Pharmaceuticals & Biotechnology?

Compare Akums Drugs & Pharmaceuticals Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Akums Drugs & Pharmaceuticals Ltd — Quarterly revenue & net profit

Revenue Net Profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹1.2K Cr, net profit ₹81 Cr.

Full financials →

📊 Revenue & Sales Performance

→CDMO segment expects double-digit volume growth in H1 FY27; overall revenue growth guidance not specifically stated yet.
→European CDMO contract projected to contribute around EUR35 million annually from FY28, adding to revenue.
→Anticipated improvement in CDMO margins to mid-teens (15-16%) as international contracts scale up.
→Domestic formulations expected to grow in line with Indian Pharmaceutical Market (IPM) with double-digit top-line growth driven by volume, price, and NII growth.
→Trade generics expected to reduce EBITDA losses sizably with a goal to achieve monthly positive EBITDA within a few quarters.
→Oral solid facility expansion underway to support volume growth.
→Broad-based gains from existing and new customers, including wallet share gains from competitors and in-house production.
→International CDMO customer base expected to expand to 8-10 global customers over 2-3 years.

📈 Profitability & Margins

→CDMO business expects double-digit volume growth in H1 FY27 with similar margin profile as current (around 13-14%) and potential improvement due to new European and Zambia contracts leading to better margins (potentially 15-16%).
→API business is expected to perform better than FY26 with reduced EBITDA losses; potential turnaround over next couple of quarters but full-year positivity uncertain.
→Trade generics business has turned EBITDA positive and is expected to maintain similar revenue and EBITDA levels without significant growth contribution.
→Domestic formulations aim for double-digit top-line growth in FY27, driven by price, volume, and NII growth, recovering in line with overall Indian Pharmaceutical Market (IPM).
→Overall margin improvements and profitability to come from ramping up new facilities, operational leverage, and inorganic opportunities.
→Tax rate expected around 29% going forward as API and trade generics businesses improve.
→No explicit guidance on EPS but improving profitability and operating leverage indicate positive earnings momentum.

See what Akums Drugs & Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.

🏗️ Capital Expenditure Plans

→Current capex for FY26 was INR 222 crores; targeted capex for FY27 is INR 300 crores.
→Ongoing expansion of the oral solid facility to support over 20% volume growth.
→Investment in ramping up new injectable, Penem, and Baddi plants progressing with client audits and product approvals underway.
→No plans for new facilities or new dosage forms specifically for international CDMO; focus is on utilizing existing advanced injectable and hormone facilities.
→Evaluating inorganic opportunities in branded portfolios, though current market valuations are high.
→SAP S/4HANA digital transformation and Darwinbox HR implementation underway for operational efficiency.
→Acquisition and expansion of land in Haridwar for capacity expansion and utility support.
→Capital deployment focus on organic expansions and strategic inorganic acquisitions aligned with growth and returns.

💰 Fundraising & Capital Structure

→There is no explicit mention of any current or planned fundraising through debt or equity in the earnings call transcript.
→The company maintains a strong liquidity position with cash and cash equivalents of INR1,682 crores.
→The focus is on utilizing existing cash and cash flows for organic expansion (e.g., oral solid facility ramp-up) and inorganic growth opportunities.
→Management emphasizes capital deployment in growth initiatives rather than external fundraising at this time.
→No comments were made on raising fresh capital through equity or debt during the call or in the discussed pages.

See what Akums Drugs & Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.

📋 Order Book & Pipeline

→The company is actively engaged with 8 to 10 global CDMO customers expected over the next 2-3 years.
→For FY28, export CDMO revenues are projected around EUR70 million (approximately INR680 crores).
→The European contract alone is expected to deliver about EUR35 million on a MAT basis annually starting FY28.
→The Zambia contract will contribute approximately $25 million annually in FY27 and FY28.
→These long-term contracts have a ramp-up period of 2-3 years due to dossier clearances and regulatory approvals.
→The order book strength stems from established products and predictable volumes, with ongoing efforts in tech transfer and new product development.
→The company is consciously evaluating multiple growth opportunities but awaiting alignment on valuation and standards before capital deployment.

Key Metrics

How does Akums Drugs & Pharmaceuticals Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Akums Drugs & Pharmaceuticals Ltd

See full Pharmaceuticals & Biotechnology sector rankings

What AKUMS's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Torrent Pharmaceuticals Ltd (Q4 FY26)
Consolidated revenue for Q4 FY26 up 42%, EBITDA up 41%, margins stable at ~32% (Page 2). Key concall takeaways from Torrent Pharma.'s Q4 FY26 earnings call…
Kwality Pharmaceuticals Ltd (Q4 FY26)
FY26: Achieved INR503 crores revenue; oncology contributed INR100-120 crores. Key concall takeaways from Kwality Pharmaceuticals Ltd's Q4 FY26 earnings call…
RPG Life Sciences Ltd (Q4 FY26)
Domestic formulation growth driven by strong volume expansion (~9.8% volume growth in Q4 FY26 vs 1.1% industry) and new product launches (5.1% growth vs 2%…
SAIPARENT (Q4 FY26)
Long-term growth supported by over 50% revenue from long-term CDs contracts in regulated markets. Key concall takeaways from Sai Parenteral's's Q4 FY26…

Compare:vs SUNPHARMA vs Divis Laboratories Ltd vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Akums Drugs & Pharmaceuticals Ltd Q4 FY26 results?

What is Akums Drugs & Pharmaceuticals Ltd share price analysis?

Akums Drugs & Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 37.5 with a market cap of ₹11,436 Cr. Investors should review the full earnings analysis for detailed insights.

Is Akums Drugs & Pharmaceuticals Ltd planning capital expenditure?

Current capex for FY26 was INR 222 crores; targeted capex for FY27 is INR 300 crores.

Keep Akums Drugs & Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.